The idea that the government is a low-tech place where projects move slowly has chilled the willingness of lawmakers to fund ambitious, tech-driven projects within the government. And it’s stifled the movement of talented people into government service roles.
In a conversation at Fast Company‘s Innovation Festival Thursday, ex-Google CEO Eric Schmidt, Rhode Island governor Gina Raimondo, and Booz Allen Hamilton chief innovation officer Susan Penfield argued that the government needs to embark on a charm offensive to prove that big-time, game-changing innovation isn’t strictly confined to the private sector.
According to Penfield of Booz Allen Hamilton, the government doesn’t entirely deserve its low-tech reputation.
“There’s amazing work going on every day, and it really takes leadership . . . from the federal sector to really tout the things they’re doing,” Booz Allens’s Penfield said. “If you think about the government, they’re
OptimizeRx (OPRX) is a stock that many stripes of investors could love. They appear to be a small cap company in a solid uptrend with a history of double digit revenue growth.
And the most exciting part is that they look to be an up and coming telehealth name akin to Teladoc (TDOC) but with the caveat that they have largely flown under the radar of big institutional investors.
Things are unfortunately a bit more complicated at OptimizeRx, with the largest issue being that we have very real reasons to be concerned with the accuracy of OPRX’s financial statements. But first I will parse OPRX’s flowery description of their business and demonstrate that they are largely a simple advertising company that provides digital coupons.
Clipping coupons does not = the next Teladoc
Below is language from OPRX’s latest 10-k describing their business: